Introduction to and update of "cost effectiveness in new technology in cervix cancer screening".
Robinowitz
Max
M
Division of Clinical Laboratory Devices, Office of Device Evaluation, Center for Devices and Radiologic Health, Food and Drug Administration, Rockville, MD 20850, USA. myr@cdrh.fda.gov
D003362:Cost-Benefit Analysis; D003936:Diagnosis, Computer-Assisted / Q000191:economics*; D005260:Female; D006801:Humans; D008403:Mass Screening / Q000191:economics* / Q000379:methods*; D011358:Product Surveillance, Postmarketing; D013673:Technology Assessment, Biomedical; D014481:United States; D014486:United States Food and Drug Administration; D002583:Uterine Cervical Neoplasms / Q000175:diagnosis*; D014626:Vaginal Smears